| Metric | Q3 2027 | Q3 2026 |
|---|---|---|
| Net income | — | -128.0 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
10-Q filed with the SEC, NYSE: RCUS. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Arcus Biosciences, Inc.: key numbers
- Share price
- $16.86Close, Nov 16
- Market cap
- $2.43B
- Shares outstanding
- 143.99MLatest SEC cover page
- Sector
- Life Sciences
- Industry
- Pharmaceutical PreparationsSIC 2834
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Arcus Biosciences, Inc.
All →Arcus Biosciences Financial Results
Arcus Biosciences reported third-quarter 2026 financial results, ending the period with $694 million in cash and marketable securities. The company highlighted clinical progress for its HIF-2α inhibitor, casdatifan, with Phase 3 enrollment for the PEAK-1 study in kidney cancer expected to complete within three months.
“In October, we showed for the first time that robust and durable HIF-2α inhibition from casdatifan can address the needs of patients at every line of kidney cancer therapy: rapid and sustained disease control in the first line, durable benefit and potential survival advantage in the second line, even after a prior TKI-inclusive therapy, and nearly three years of median overall survival in late-line patients who had exhausted multiple therapies.”
Terry Rosen, Ph.D., chief executive officer of Arcus
“With PEAK-1 enrollment nearing completion and PEAK-20 set to begin by year-end, we are building the registrational evidence to make casdatifan the backbone of treatment across the continuum of care for clear cell renal cell carcinoma.”
Terry Rosen, Ph.D., chief executive officer of Arcus
Arcus Biosciences Capital Raise of $288M
Arcus Biosciences completed a public offering of 16,428,572 shares of common stock, including the full exercise of the underwriters' option to purchase additional shares. The offering was priced at $17.50 per share, resulting in net proceeds of approximately $269.7 million after fees and expenses.
- Value
- $288M
- Counterparty
- Jefferies LLC, Leerink Partners LLC and TD Securities (USA) LLC
Arcus Biosciences Business Update
Arcus Biosciences provided a preliminary estimate of its cash position, reporting approximately $694.0 million in cash, cash equivalents, and marketable securities as of September 30, 2026. This figure is an unaudited estimate released ahead of the company's full quarterly financial results.
Arcus Biosciences Clinical Trial Data
Arcus Biosciences presented new data from its ARC-20 platform study evaluating casdatifan in various treatment lines for clear cell renal cell carcinoma (ccRCC). Key results included a 50% confirmed objective response rate (cORR) for the first-line casdatifan plus zimberelimab combination and a 14.5-month median progression-free survival for the second-line combination with cabozantinib.